| [1] |
Siegel RL, Giaquinto AN, Jemal A. Cancer Statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49. DOI: 10.3322/caac.21820.
|
| [2] |
Park B. Associations between obesity, metabolic syndrome, and endometrial cancer risk in East Asian women[J]. J Gynecol Oncol, 2022, 33(4): e35. DOI: 10.3802/jgo.2022.33.e35.
|
| [3] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
|
| [4] |
Jo H, Kim SI, Wang W, et al. Metabolic syndrome as a risk factor of endometrial cancer: a nationwide population-based cohort study of 2.8 million women in South Korea[J]. Front Oncol, 2022, 12: 872995. DOI: 10.3389/fonc.2022.872995.
|
| [5] |
Winarto H, Ibrahim NAA, Putri YM, et al. Adjuvant chemoradiotherapy versus chemotherapy or radiotherapy in advanced endometrial cancer: a systematic review and Meta-analysis[J]. Peer J, 2022, 10: e14420. DOI: 10.7717/peerj.14420.
|
| [6] |
Gallo A, Catena U, Saccone G, et al. Conservative surgery in endometrial cancer[J]. J Clin Med, 2021, 11(1): 183. DOI: 10.3390/jcm11010183.
|
| [7] |
Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer[J]. Int J Gynecol Cancer, 2016, 26(1): 2-30. DOI: 10.1097/IGC.0000000000000609.
|
| [8] |
Guan X, Tang R, Yang J. Endocrine therapy for endometrial cancer: traditional approaches and novel targets[J]. Front Oncol, 2025, 15: 1570011. DOI: 10.3389/fonc.2025.1570011.
|
| [9] |
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma[J]. Nature, 2013, 497(7447): 67-73. DOI: 10.1038/nature12113. |
| [10] |
Alexa M, Hasenburg A, Battista MJ. The TCGA molecular classification of endometrial cancer and its possible impact on adjuvant treatment decisions[J]. Cancers, 2021, 13(6): 1478. DOI: 10.3390/cancers13061478.
|
| [11] |
Hodgson A, Han K. Endometrial cancer classification and management in the molecular subtyping era[J]. JAMA Oncol, 2024, 10(12): 1723. DOI: 10.1001/jamaoncol.2024.4376.
|
| [12] |
Perrone AM, De Leo A, Biase DD, et al. Endometrial carcinoma: past, present, and future[J]. Eur J Gynaecol Oncol, 2021, 42(4): 610. DOI: 10.31083/j.ejgo4204094.
|
| [13] |
Galant N, Krawczyk P, Monist M, et al. Molecular classification of endometrial cancer and its impact on therapy selection[J]. Int J Mol Sci, 2024, 25(11): 5893. DOI: 10.3390/ijms25115893.
|
| [14] |
Jamieson A, McAlpine JN. Molecular profiling of endometrial cancer from TCGA to clinical practice[J]. J Natl Compr Canc Netw, 2023, 21(2): 210-216. DOI: 10.6004/jnccn.2022.7096.
|
| [15] |
Barretina-Ginesta MP, Quindós M, Alarcón JD, et al. SEOM-GEICO clinical guidelines on endometrial cancer (2021)[J]. Clin Transl Oncol, 2022, 24(4): 625-634. DOI: 10.1007/s12094-022-02799-7.
|
| [16] |
Zugasti I, Espinosa-Aroca L, Fidyt K, et al. CAR-T cell therapy for cancer: current challenges and future directions[J]. Signal Transduct Target Ther, 2025, 10(1): 210. DOI: 10.1038/s41392-025-02269-w.
|
| [17] |
Wang KH, Chang YH, Harnod T, et al. Endometrial cancer-infiltrating mesenchymal stem cells exhibit immunosuppressive effects[J]. Cell Transplant, 2022, 31: 09636897221104452. DOI: 10.1177/09636897221104452.
|
| [18] |
Berger AC, Korkut A, Kanchi RS, et al. A comprehensive pan-cancer molecular study of gynecologic and breast cancers[J]. Cancer Cell, 2018, 33(4): 690-705.e9. DOI: 10.1016/j.ccell.2018.03.014.
|
| [19] |
Ngwa W, Irabor OC, Schoenfeld JD, et al. Using immunotherapy to boost the abscopal effect[J]. Nat Rev Cancer, 2018, 18(5): 313-322. DOI: 10.1038/nrc.2018.6.
|
| [20] |
O′Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study[J]. J Clin Oncol, 2022, 40(7): 752-761. DOI: 10.1200/JCO.21.01874.
|
| [21] |
Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer[J]. N Engl J Med, 2023, 388(23): 2145-2158. DOI: 10.1056/NEJMoa2216334.
|
| [22] |
Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer[J]. N Engl J Med, 2023, 388(23): 2159-2170. DOI: 10.1056/NEJMoa2302312.
|
| [23] |
Westin SN, Moore K, Chon HS, et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase Ⅲ DUO-E trial[J]. J Clin Oncol, 2024, 42(3): 283-299. DOI: 10.1200/JCO.23.02132.
|
| [24] |
Mirza MR, Coleman RL, Hanker L, et al. 820TiP ENGOT-EN6/GOG-3031/NSGO-CTU-RUBY part 2: a phase Ⅲ，randomized, double-blind, study of dostarlimab ＋ carboplatin-paclitaxel followed by dostarlimab ＋ niraparib versus placebo (PBO) ＋ carboplatin-paclitaxel followed by PBO in recurrent or advanced endometrial cancer (EC) [J]. Ann Oncol, 2021, 32: S770-S771. DOI: 10.1016/j.annonc.2021.08.1262.
|
| [25] |
Mirza M, Ghamande S, Hanker L, et al. Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial[J]. Gynecol Oncol, 2024, 190: S6. DOI: 10.1016/j.ygyno.2024.07.016.
|
| [26] |
Alabi F, Okpalanwaka IF, Azoroh B, et al. Lenvatinib plus pembrolizumab versus chemotherapy in advanced endometrial cancer: efficacy and safety insights[J]. Cureus, 2025, 17(7): e89030. DOI: 10.7759/cureus.89030.
|
| [27] |
Lee KY, Chiang YC, Sheen JY, et al. Pembrolizumab combined with chemotherapy for advanced and recurrent endometrial cancer: a single-center retrospective study[J]. J Formos Med Assoc, 2025: S0929664625005704. DOI: 10.1016/j.jfma.2025.10.026.
|
| [28] |
Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2019, 20(5): 711-718. DOI: 10.1016/S1470-2045(19)30020-8.
|
| [29] |
Chen XJ, Zhang KQ, Wang K, et al. Benmelstobart plus carboplatin/paclitaxel with or without anlotinib, followed by maintenance benmelstobart with or without anlotinib, as first-line treatment for advanced or recurrent endometrial cancer: a randomized, open-label, phase Ⅱ trial[J]. J Clin Oncol, 2025, 43(16_suppl): 5508. DOI: 10.1200/JCO.2025.43.16_suppl.5508.
|
| [30] |
Lan C, Yang X, Zhao J, et al. Cadonilimab plus lenvatinib in patients with advanced endometrial cancer: a multicenter, single-arm, phase Ⅱ trial[J]. J Clin Oncol, 2024, 42(16_suppl): 5600. DOI: 10.1200/JCO.2024.42.16_suppl.5600.
|
| [31] |
Wen H, Wu X, Li Q, et al. Efficacy and safety of combination therapy with envafolimab and lenvatinib in patients with endometrial cancer after failure of first-line platinum-based therapy[J]. J Clin Oncol, 2024, 42(16_suppl): 5597. DOI: 10.1200/JCO.2024.42.16_suppl.5597.
|
| [32] |
Wu X, Wang J, Wang D, et al. Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ⅰb/Ⅱ trial[J]. Nat Commun, 2025, 17(1): 658. DOI: 10.1038/s41467-025-67375-3.
|
| [33] |
Ibanez KR, Huang TT, Lee JM. Combination therapy approach to overcome the resistance to PI3K pathway inhibitors in gynecological cancers[J]. Cell, 2024, 13(12): 1064. DOI: 10.3390/cells13121064.
|
| [34] |
Wei J, Li W, Zhang P, et al. Current trends in sensitizing immune checkpoint inhibitors for cancer treatment[J]. Mol Cancer, 2024, 23(1): 279. DOI: 10.1186/s12943-024-02179-5.
|
| [35] |
Chelariu-Raicu A, Mahner S, Moore KN. Integrating antibody drug conjugates in the management of gynecologic cancers[J]. Int J Gynecol Cancer, 2023, 33(3): 420-429. DOI: 10.1136/ijgc-2022-003701.
|
| [36] |
Cristea MC, Stewart D, Synold T, et al. A phase Ⅰ study of mirvetuximab soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer[J]. Gynecol Oncol, 2024, 182: 124-131. DOI: 10.1016/j.ygyno.2023.12.017.
|
| [37] |
Kim GR, Choi JM. Current understanding of cytotoxic T lymphocyte antigen-4 (CTLA-4) signaling in T-cell biology and disease therapy[J]. Mol Cells, 2022, 45(8): 513-521. DOI: 10.14348/molcells.2022.2056.
|
| [38] |
Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation[J]. Immunity, 2024, 57(2): 206-222. DOI: 10.1016/j.immuni.2024.01.010.
|
| [39] |
Rojas C, Eskens F, Ghiringhelli F, et al. Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair-deficient (dMMR) endometrial cancer: results from cohort B1 of the phase 2 KEYVIBE-005 study[J]. J Clin Oncol, 2024, 42(16_suppl): 5502-5502. DOI: 10.1200/JCO.2024.42.16_suppl.5502.
|
| [40] |
Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma[J]. N Engl J Med, 2012, 366(10): 925-931. DOI: 10.1056/NEJMoa1112824.
|
| [41] |
RAINBO Research Consortium. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program[J]. Int J Gynecol Cancer, 2023, 33(1): 109-117. DOI: 10.1136/ijgc-2022-004039. |
| [42] |
Palomero J, Panisello C, Lozano-Rabella M, et al. Biomarkers of tumor-reactive CD4 ＋ and CD8 ＋ TILs associate with improved prognosis in endometrial cancer[J]. J Immunother Cancer, 2022, 10(12): e005443. DOI: 10.1136/jitc-2022-005443.
|
| [43] |
Ozturk C, Askan G, Ozturk SD, et al. High tumor infiltrating lymphocytes are associated with overall survival and good prognostic parameters in endometrial endometrioid carcinoma patients[J]. Turk J Pathol, 2022, 39: 75-82. DOI: 10.5146/tjpath.2022.01596.
|
| [44] |
Yu Z, Shi J, Fang Y, et al. Developing innovative strategies of tumor infiltrating lymphocyte therapy for tumor treatment[J]. Oncol Rep, 2024, 51(6): 85. DOI: 10.3892/or.2024.8744.
|
| [45] |
Araki H, Tazawa H, Kanaya N, et al. Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer[J]. Mol Ther Oncolytics, 2022, 27: 3-13. DOI: 10.1016/j.omto.2022.09.003.
|
| [46] |
Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review[J]. Eur J Cancer, 2016, 54: 139-148. DOI: 10.1016/j.ejca.2015.11.016.
|
| [47] |
Zhao L, Li X, Jing Y, et al. Biomarkers and immunotherapy in endometrial cancer: mechanisms and clinical applications[J]. Front Immunol, 2025, 16: 1684549. DOI: 10.3389/fimmu.2025.1684549.
|